GlassScriptPhysician profile
Maja Strollo
NPI 1154028009
$5,921.66
in general payments reported to CMS, 2019-2025
32 companies · $2,831 in 2025
The $2,831 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,203 · 2024: $1,887 · 2025: $2,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,826 · Education: $95.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,826.18 |
| Education | $95.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,206.18 | 2023-2025 | |
| Janssen Biotech, INC. | $550.45 | 2023-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $436.14 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $420.64 | 2023-2025 | |
| Pfizer INC. | $339.75 | 2023-2025 | |
| Qol Medical, LLC | $325.81 | 2023-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.66 | 2023-2025 | Xifaxan, Trulance |
| Celgene Corporation | $286.41 | 2023-2024 | Zeposia |
| Genzyme Corporation | $259.37 | 2023-2025 | |
| Ardelyx, INC. | $244.33 | 2023-2025 | Ibsrela |
| Novo Nordisk INC | $206.29 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $180.23 | 2024-2025 | Zenpep, Vowst |
| Ipsen Biopharmaceuticals, INC | $174.75 | 2024-2025 | Iqirvo, Bylvay |
| Lilly USA, LLC | $174.55 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $142.62 | 2023-2025 | Zymfentra, Vegzelma, Yuflyma |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $142.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $68.76 | 2024-2025 | Voquezna |
| Pharmacosmos Therapeutics INC. | $53.91 | 2023-2025 | Monoferric |
| Daiichi Sankyo INC. | $50.18 | 2023-2024 | Injectafer |
| Biocon Biologics INC | $48.18 | 2025 | Yesintek |
| Regeneron Healthcare Solutions, INC. | $37.41 | 2023-2024 | Dupixent |
| Ferring Pharmaceuticals INC. | $36.92 | 2023 | Rebyota |
| Alnylam Pharmaceuticals INC. | $36.38 | 2023-2025 | Givlaari |
| Intercept Pharmaceuticals, INC. | $33.51 | 2024-2025 | |
| Vivus LLC | $28.46 | 2024-2025 | Pancreaze, Qsymia |
| Merck Sharp & Dohme LLC | $26.21 | 2023 | Dificid |
| Mirum Pharmaceuticals, INC. | $24.47 | 2025 | Livmarli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.07 | 2024 | Cyltezo |
| Nestle Healthcare Nutrition INC. | $22.15 | 2023 | |
| W. L. Gore & Associates, INC. | $16.64 | 2023 | Gore Cardioform Septal Occluder |
| Redhill Biopharma INC. | $16.06 | 2023 | Talicia |
| Sandoz INC. | $14.78 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maja Strollo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.